[1]Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology[J]. Medicine (Baltimore), 2006, 85(1): 37-42.
[2]Parish JM, Marschke RF Jr, Dines DE, et al. Etiologic considerations in superior vena cava syndrome[J]. Mayo Clin Proc, 1981, 56(7):407-413.
[3]Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes[J]. N Engl J Med, 2007, 356(18):1862-1869.
[4]Armstrong BA, Perez CA, Simpson JR, et al. Role of irradiation in the management of superior vena cava syndrome[J]. Int J Radiat Oncol Biol Phys, 1987, 13(4):531-539.
[5]Pluta E, Blecharz P, Reinfuss M, et al. Superior vena cava syndrome in patients with lung cancer - the role of radiotherapy: Part Ⅱ. Efficacy, complications and prognostic factors[J]. Onkologia I Radioterapia, 2011, 17(3):41-46
[6]Beeson MS, Port JL. Superior vena cava syndrome[J]. Encyclopedia of Diagnostic Imaging, 2006, 233(5):1775.
[7]Kim HJ, Kim HS, Chung SH. CT diagnosis of superior vena cava syndrome: importance of collateral vessels[J]. AJR Am J Roentgenol, 1993, 161(3):539-542.
[8]Mineo TC, Ambrogi V, Nofroni I, et al. Mediastinoscopy in superior vena cava obstruction: analysis of 80 consecutive patients[J]. Ann Thorac Surg, 1999, 68(1):223-226.
[9]Hossen MM, Rabbani R, Hasan M. Oncologic Emergencies[J]. American Family Physician, 2014, 31(3):104-114.
[10]Krimsky WS, Behrens RJ, Kerkvliet GJ. Oncologic emergencies for the internist[J]. Cleve Clin J Med, 2002, 69(3):209-210, 213-214, 216-217.
[11]Jahangiri M, Goldstraw P. The role of mediastinoscopy in superior vena caval obstruction[J]. Ann Thorac Surg, 1995, 59(2):453-455.
[12]Haffy BG, Wilson LD. Palliation and oncologic emergencies[M]// Handbook of radiation oncology. Jones And Bartlett Publishers, 2009:159-172.
[13]Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome-〖JP〗a proposed classification system and algorithm for management[J]. J Thorac Oncol, 2008, 3(8):811-814.
[14]MT Mccurdy, Shanholtz CB. Oncologic emergencies[J]. Crit Care Med, 2012, 40(7):2212-2222.
[15]Ganeshan A, Hon LQ, Warakaulle DR, et al. Superior vena caval stenting for SVC obstruction: current status[J]. Eur J Radiol, 2009, 71(2):343-349.
[16]Marcy PY, Magné N, Bentolila F, et al. Superior vena cava obstruction: Is stenting necessary[J]. Support Care Cancer, 2001, 9(2):103-107.
[17]Ecker RD, Endo T, Wetjen NM, et al. Diagnosis and treatment of vertebral column metastases[J].Mayo Clinic Proc, 2005, 80(9):1177-1186.
[18]Bach F, Larsen BH, Rohde K, et al. Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression[J]. Acta Neurochir (Wien), 1990, 107(1-2):37-43.
[19]Loblaw DA, Smith K, Lockwood G, et al. The Princess Margaret Hospital experience of malignant spinal cord compression[C]. Proc Am Soc Clin Oncol, 2003, 22: 119.
[20]Schiff D. Spinal cord compression[J]. Neurolclin, 2003, 21(1): 67-86.
[21]Loblaw DA, Laperriere NJ, Mackillop WJ. A population-based study of malignant spinal cord compression in Ontario[J]. Clin Oncol(R Coll Radiol), 2003, 15(4): 211-217.
[22]Jacobs WB, Perrin RG. Evaluation and treatment of spinal metastases: an overview[J]. Neurosurgical Focus, 2001, 11(6):e10.
[23]Prasad D, Schiff D. Malignant spinal-cord compression[J]. Lancet Oncol, 2005, 6(1): 15-24.
[24]Schiff D, Batchelor T, Wen PY. Neurologic emergencies in cancer patients[J]. Neurol Clin, 1998, 16(2): 449-483.
[25]Quint DJ. Indications for emergent MRI of the central nervous system[J]. JAMA, 2000, 283(7): 853-855.
[26]Husband DJ, Grant KA, Romaniuk CS. MRI in the diagnosis and treatment of suspected malignant spinal cord compression[J]. Br J Radiol, 2001, 74(877): 15-23.
[27]Portenoy RK, Galer BS, Salamon O, et al. Identification of epidural neoplasm. Radiography and bone scintigraphy in the symptomatic and asymptomatic spine[J]. Cancer, 1989, 64(11): 2207-2213.
[28]Yeung SCJ, Escalante CP. Oncologic emergencies[M]. Am J Nursing, 1983, 83(9):1283-1285.
[29]Loblaw DA, Perry J, Chambers A, et al. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative’s Neuro-Oncology Disease Site Group[J]. J Clin Oncol, 2005, 23(9): 2028-2037.
[30]Bilsky MH, Lis E, Raizer J, et al. The diagnosis and treatment of metastatic spinal tumor[J]. Oncologist, 1999, 4(6): 459-469.
[31]Brigden ML. Hematologic and oncologic emergencies. Doing the most good in the least time[J]. Postgraduate Medicine, 2001, 109(3): 143-146.
[32]Kvale PA, Simoff M, Prakash UB. Lung cancer. Palliative care[J]. Chest, 2003, 123(1suppl): 284S-311S.
[33]Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial[J]. Lancet, 2005, 366(9486): 643-648.
[34]Klimo P Jr, Schmidt MH. Surgical management of spinal metastases[J]. Oncologist, 2004, 9(2): 188-196.
[35]Halfdanarson TR, Hogan WJ, Moynihan TJ. Oncologic emergencies: diagnosis and treatment[C]. Mayo Clinic Proceedings, Elsevier, 2006, 81(6): 835-848.
[36]Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System[J]. J Clin Oncol, 2004, 22(14): 2865-2872.
[37]Behl D, Hendrickson AW, Moynihan TJ, et al. Oncologic emergencies[J]. Crit Care Clin, 2010, 26(1):181-205.
[38]Tosoni A, Ermani M, Brandes AA. The pathogenesis and treatment of brain metastases: a comprehensive review[J]. Crit Rev Oncol Hematol, 2004, 52(3): 199-215.
[39]Dunn LT. Raised intracranial pressure[J]. J Neurol Neurosurg Psychiatry, 2002, 73(suppl 1): i23-i27.
[40]Kaal EC, Vecht CJ. The management of brain edema in brain tumors[J]. Curr Opin Oncol, 2004, 16(6): 593-600.
[41]Christiaans MH, Kelder JC, Arnoldus EP, et al. Prediction of intracranial metastases in cancer patients with headache[J]. Cancer, 2002, 94(7): 2063-2068.
[42]Klos KJ, O’Neill BP. Brain metastases[J]. Neurologist, 2004, 10(1): 31-46.
[43]Nutt SH, Patchell RA. Intracranial hemorrhage associated with primary and secondary tumors[J]. Neurosurg Clin N Am, 1992, 3(3):591-599.
[44]Kaal EC, Nil CG, Vecht CJ. Therapeutic management of brain metastasis[J]. Lancet Neurol, 2005, 4(5):289-298.
[45]Jarden JO, Dhawan V, Moeller JR, et al. The time course of steroid action on blood-to-brain and blood-to-tumor transport of 82Rb: a positron emission tomographic study[J]. Ann Neurol, 1989, 25(3):239-245.
[46]Batchelor T, Deangelis LM. Medical management of cerebral metastases[J]. Neurosurg Clin N Am, 1996, 7(3):435-446.
[47]Peacock KH, Lesser GJ. Current therapeutic approaches in patients with brain metastases[J]. Curr Treat Options Oncol, 2006, 7(6):479-489.
[48]Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment[J]. CA Cancer J Clin, 2011, 61(5):287-314.[49]Tsao MN, Lloyd NS, Wong RK, et al. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis[J]. Cancer Treat Rev, 2005, 31(4): 256-273.
[50]Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers[J]. Arch Intern Med, 2006, 166(4):458-464.
[51]Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients[J]. J Clin Oncol, 2006, 24(3):484-490.
[52]Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy[J]. J Thromb Haemost, 2007, 5(3):632-634.
[53]Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management[J]. Ann Oncol, 2005, 16(5):696-791.
[54]Seddighzadeh A, Shetty R, Goldhaber SZ. Venous thromboembolism in patients with active cancer[J]. Thromb Haemost, 2007, 98(3):656-661.
[55]Agnelli G, Verso M, Ageno W, et al. The MASTER registry on venous thromboembolism: description of the study cohort[J]. Thromb Res, 2008, 121(5):605-610.
[56]Linenberger ML. Catheter-related thrombosis: risks, diagnosis, and management[J]. J Natl Compr Canc Netw, 2006, 4(9):889-901.
[57]Carrier M, Lee AY, Bates SM, et al. Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients[J]. ThrombRes, 2008, 123(1):177-183.
[58]Rosovsky RP, Kuter DJ. Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management[J]. Hematol Oncol Clin North Am, 2005, 19(1):183-202.
[59]Van Belle A, Büller HR, Huisman MV, et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography[J]. JAMA, 2006, 295(2):172-179.
[60]Stein PD, Woodard PK, Weg JG, et al. Diagnostic pathways in acute pulmonary embolism: recommendations of The PIOPEDⅡInvestigators[J]. Radiology, 2007, 242(1):15-21.
[61]Mandalà M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2011, 22(suppl_6):vi85-92.
[62]Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis[J]. Ann Surg, 1988, 208(2):227-240.
[63]Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stageⅣbreast cancer[J]. Lancet, 1994, 343(8902):886-889.
[64]Stewart AF.Clinical practice. Hypercalcemia Associated with Cancer[J]. N Engl J Med, 2005, 352(4):373-379.
[65]Body JJ. Hypercalcemia of malignancy[J]. Semin Nephrol, 2004, 24(1):48-54.
[66]Ralston SH, Gallacher SJ, Patel U, et al. Cancer-associated hypercalcemia: morbidity and mortality: Clinical experience in 126 treated patients[J]. Ann Intern Med, 1990, 112(7):499-504.
[67]Wimalawansa SJ. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate[J]. Cancer, 1994, 73(8):2223-2230.
[68]Glass DA 2nd, Patel MS, Karsenty G. A new insight into the formation of osteolytic lesions in multiple myeloma[J]. N Engl J Med, 2003, 349(26):2479-2480.
[69]Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin′s and non-Hodgkin′s lymphomas[J]. Blood, 1993, 82(5):1383-1394.
[70]Deftos LJ. Hypercalcemia in malignant and inflammatory diseases[J]. Endocrinol Metab Clin North Am, 2002, 31(1):141-158.
[71]Myers WP. Differential diagnosis of hypercalcemia and cancer[J]. CA Cancer J Clin, 1977, 27(5):258-272.
[72]John R, Oleesky D, Issa B, et al. Pseudohypercalcaemia in two patients with IgM paraproteinaemia[J]. Ann Clin Biochem, 1997, 34 (Pt 6):694-696.
[73]Ladenson JH, Lewis JW, McDonald JM, et al. Relationship of free and total calcium in hypercalcemic conditions[J]. J Clin Endocrinol Metab, 1979, 48(3):393-397.
[74]Stewart AF. Clinical practice. Hypercalcemia associated with cancer[J]. N Engl J Med, 2005, 352(4):373-379.
[75]Ratcliffe WA, Hutchesson AC, Bundred NJ, et al. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia[J]. Lancet, 1992, 339(8786):164-167.
[76]Santarpia L, Koch CA, Sarlis NJ. Hypercalcemia in cancer patients: pathobiology and management[J]. Horm Metab Res, 2010, 42(3):153-164.
[77]Koo WS, Jeon DS, Ahn SJ, et al. Calcium-free hemodialysis for the management of hypercalcemia[J]. Nephron, 1996, 72(3):424-428.
[78]3Rd VA, O′Neal W, Palermo V. Lethal hyperparathyroid crisis:hazards of phosphate administration[J]. Surgery, 1987, 102(6):941-948.